Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 13,466 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Pancreatic Cancer
Interventions: EGD with EUS, 4D-ELF; Procedure · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Gastroenteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm
Interventions: NETest; Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Premature Ovarian Insufficiency, Diminished Ovarian Reserve
Interventions: VL-PX10; Drug
Lead sponsor: Vitti Labs, LLC; Industry
Eligibility: 18 Years to 43 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Diabetes Mellitus, Type 2
Interventions: Low-fat, low-Glycemic Index, vegan diet, ADA diet; Behavioral
Lead sponsor: Physicians Committee for Responsible Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
Interventions: disitamab vedotin; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 75
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 36 more

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: NNC 90-1170; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 30 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Down Syndrome, Edwards Syndrome, Patau Syndrome, Klinefelter Syndrome, Turner Syndrome, DiGeorge Syndrome, Chromosome Deletion, Aneuploidy
Interventions: Blood sampling for Laboratory Developed Test (LDT) analysis; Other
Lead sponsor: Progenity, Inc.; Industry
Eligibility: 18 Years to 54 Years · Female only
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 8
States / cities: Scottsdale, Arizona • Eunice, Louisiana • Brooklyn, New York + 5 more

Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Bevacizumab, Gemcitabine Hydrochloride, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride; Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Diabetes, Type 1 Diabetes, Young Adult, Diabetes Mellitus
Interventions: T1D-CATCH; Behavioral
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 35 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Thyroid Eye Disease, Graves' Orbitopathy
Interventions: Teprotumumab; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
U.S. locations: 8
States / cities: Beverly Hills, California • Miami, Florida • Skokie, Illinois + 5 more

Conditions: Obstructive Sleep Apnea, Diabetes Mellitus
Interventions: PreDx Diabetes Risk Score; Behavioral
Lead sponsor: Mike O'Callaghan Military Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: PreDiabetes, Sedentary Lifestyle
Interventions: 6-week exercise training program, Standardized isoenergetic high fat diet; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 60 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Winston-Salem, North Carolina

Conditions: Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Gallbladder Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Gallbladder Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Cancer
Interventions: Cisplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pharmacological Study, Recombinant EphB4-HSA Fusion Protein; Drug · Other · Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 2
States / cities: Los Angeles, California • Newport Beach, California

Conditions: Cancer
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2015
U.S. locations: 1
States / cities: Duarte, California

Conditions: Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor, Breast Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, Liver Cancer, Angiosarcoma, Solid Tumor
Interventions: AGX101; Drug
Lead sponsor: Angiex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Los Angeles, California • Sarasota, Florida • St Louis, Missouri + 4 more

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: INGAP-Peptide, placebo; Drug
Lead sponsor: Exsulin Corporation; Industry
Eligibility: 35 Years to 70 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 17
States / cities: La Jolla, California • San Diego, California • Walnut Creek, California + 13 more

Conditions: Diabetes, Glycinemia
Interventions: Usual standard of care, Neuropsychological Consultation; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 10 Years to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Bevacizumab, Fosbretabulin Tromethamine, Laboratory Biomarker Analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 51
States / cities: Phoenix, Arizona • Burbank, California • Concord, California + 40 more

Conditions: Diabetes (DM)
Interventions: Glucagon, Saline (placebo); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Type 2 Diabetes
Interventions: virtual world, face to face; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Thyroid Cancer
Interventions: Bexarotene; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Ovulation Disorder, Ovarian Cysts
Interventions: Letrozole; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly
Interventions: Not listed
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Diabetes Mellitus, Hyperglycemia
Interventions: Not listed
Lead sponsor: Dental Practice-Based Research Network; Network
Eligibility: 19 Years and older
Enrollment: 498 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Birmingham, Alabama • Gainesville, Florida • Minneapolis, Minnesota + 1 more

Search by objective public record fields.

Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer

Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors

A Proof of Concept Study to Evaluate Exosomes From Human Mesenchymal Stem Cells in Women With Premature Ovarian Insufficiency (POI)

Plant-Based Dietary Intervention in Type 2 Diabetes-2

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes

Expanded Noninvasive Genomic Medical Assessment: The Enigma Study

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

T1DTechCHW: Enhancing the Community Health Worker Model to Promote Diabetes Technology Use in Young Adults From Underrepresented Minority Groups

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease

Assessing the Risk of Developing Type II Diabetes Using Serum Biomarkers in Patients Diagnosed With Obstructive Sleep Apnea

Exercise Training and Metabolic Flexibility in Prediabetes

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes

Neuropsychological Consultation as Part of Pediatric Diabetes Care: Does it Improve Glycemic Control and Family Functioning?

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Studies of Insulin and Glucagon Action in the Liver

Virtual World Health Behavior Counseling for Patients With Diabetes

A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression

The Role of Estrogen in Luteinizing Hormone Surge and Ovulation

A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly

DPBRN Blood Sugar Testing in Dental Patients